Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Cortico-Striatal Cross-Frequency Coupling and Gamma Genesis Disruptions in Huntington's Disease Mouse and Computational Models.

Naze S, Humble J, Zheng P, Barton S, Rangel-Barajas C, Rebec GV, Kozloski JR.

eNeuro. 2018 Dec 21;5(6). pii: ENEURO.0210-18.2018. doi: 10.1523/ENEURO.0210-18.2018. eCollection 2018 Nov-Dec.

2.

Overview of Huntington's Disease Models: Neuropathological, Molecular, and Behavioral Differences.

Rangel-Barajas C, Rebec GV.

Curr Protoc Neurosci. 2018 Apr;83(1):e47. doi: 10.1002/cpns.47.

PMID:
30040221
3.

Dysregulation of Corticostriatal Connectivity in Huntington's Disease: A Role for Dopamine Modulation.

Rangel-Barajas C, Rebec GV.

J Huntingtons Dis. 2016 Dec 15;5(4):303-331. Review.

4.

Dysregulated corticostriatal activity in open-field behavior and the head-twitch response induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine.

Rangel-Barajas C, Estrada-Sánchez AM, Barton SJ, Luedtke RR, Rebec GV.

Neuropharmacology. 2017 Feb;113(Pt A):502-510. doi: 10.1016/j.neuropharm.2016.11.001. Epub 2016 Nov 2.

5.

The effect of the sigma-1 receptor selective compound LS-1-137 on the DOI-induced head twitch response in mice.

Malik M, Rangel-Barajas C, Mach RH, Luedtke RR.

Pharmacol Biochem Behav. 2016 Sep;148:136-44. doi: 10.1016/j.pbb.2016.07.001. Epub 2016 Jul 8.

PMID:
27397487
6.

Dopamine Receptors and Neurodegeneration.

Rangel-Barajas C, Coronel I, Florán B.

Aging Dis. 2015 Oct 1;6(5):349-68. doi: 10.14336/AD.2015.0330. eCollection 2015 Sep. Review.

7.

Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.

Luedtke RR, Rangel-Barajas C, Malik M, Reichert DE, Mach RH.

Curr Pharm Des. 2015;21(26):3700-24. Review.

PMID:
26205291
8.

Pharmacological modulation of abnormal involuntary DOI-induced head twitch response movements in male DBA/2J mice: II. Effects of D3 dopamine receptor selective compounds.

Rangel-Barajas C, Malik M, Mach RH, Luedtke RR.

Neuropharmacology. 2015 Jun;93:179-90. doi: 10.1016/j.neuropharm.2014.10.030. Epub 2015 Feb 17.

PMID:
25698528
9.

The effects of sigma (σ1) receptor-selective ligands on muscarinic receptor antagonist-induced cognitive deficits in mice.

Malik M, Rangel-Barajas C, Sumien N, Su C, Singh M, Chen Z, Huang RQ, Meunier J, Maurice T, Mach RH, Luedtke RR.

Br J Pharmacol. 2015 May;172(10):2519-31. doi: 10.1111/bph.13076. Epub 2015 Apr 10.

10.

Dopaminergic denervation switches dopamine D3 receptor signaling and disrupts its Ca(2+) dependent modulation by CaMKII and calmodulin in striatonigral projections of the rat.

Avalos-Fuentes A, Albarrán-Bravo S, Loya-Lopéz S, Cortés H, Recillas-Morales S, Magaña JJ, Paz-Bermúdez F, Rangel-Barajas C, Aceves J, Erlij D, Florán B.

Neurobiol Dis. 2015 Feb;74:336-46. doi: 10.1016/j.nbd.2014.12.008. Epub 2014 Dec 14.

PMID:
25517101
11.

Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Rangel-Barajas C, Malik M, Taylor M, Neve KA, Mach RH, Luedtke RR.

J Neurochem. 2014 Nov;131(4):418-31. doi: 10.1111/jnc.12825. Epub 2014 Aug 19.

12.

Pharmacological modulation of abnormal involuntary DOI-induced head twitch response in male DBA/2J mice: I. Effects of D2/D3 and D2 dopamine receptor selective compounds.

Rangel-Barajas C, Malik M, Vangveravong S, Mach RH, Luedtke RR.

Neuropharmacology. 2014 Aug;83:18-27. doi: 10.1016/j.neuropharm.2014.03.003. Epub 2014 Mar 26.

PMID:
24680675
13.

Sensitization of restraint-induced corticosterone secretion after chronic restraint in rats: involvement of 5-HT₇ receptors.

García-Iglesias BB, Mendoza-Garrido ME, Gutiérrez-Ospina G, Rangel-Barajas C, Noyola-Díaz M, Terrón JA.

Neuropharmacology. 2013 Aug;71:216-27. doi: 10.1016/j.neuropharm.2013.03.013. Epub 2013 Mar 28.

14.

D3 dopamine receptors interact with dopamine D1 but not D4 receptors in the GABAergic terminals of the SNr of the rat.

Cruz-Trujillo R, Avalos-Fuentes A, Rangel-Barajas C, Paz-Bermúdez F, Sierra A, Escartín-Perez E, Aceves J, Erlij D, Florán B.

Neuropharmacology. 2013 Apr;67:370-8. doi: 10.1016/j.neuropharm.2012.11.032. Epub 2012 Dec 10.

PMID:
23238327
15.

Dopamine D4 receptor, but not the ADHD-associated D4.7 variant, forms functional heteromers with the dopamine D2S receptor in the brain.

González S, Rangel-Barajas C, Peper M, Lorenzo R, Moreno E, Ciruela F, Borycz J, Ortiz J, Lluís C, Franco R, McCormick PJ, Volkow ND, Rubinstein M, Floran B, Ferré S.

Mol Psychiatry. 2012 Jun;17(6):650-62. doi: 10.1038/mp.2011.93. Epub 2011 Aug 16.

16.

L-DOPA-induced dyskinesia in hemiparkinsonian rats is associated with up-regulation of adenylyl cyclase type V/VI and increased GABA release in the substantia nigra reticulata.

Rangel-Barajas C, Silva I, Lopéz-Santiago LM, Aceves J, Erlij D, Florán B.

Neurobiol Dis. 2011 Jan;41(1):51-61. doi: 10.1016/j.nbd.2010.08.018. Epub 2010 Aug 22.

PMID:
20736067
17.

6-OHDA-induced hemiparkinsonism and chronic L-DOPA treatment increase dopamine D1-stimulated [(3)H]-GABA release and [(3)H]-cAMP production in substantia nigra pars reticulata of the rat.

Rangel-Barajas C, Silva I, García-Ramírez M, Sánchez-Lemus E, Floran L, Aceves J, Erlij D, Florán B.

Neuropharmacology. 2008 Oct;55(5):704-11. doi: 10.1016/j.neuropharm.2008.06.002. Epub 2008 Jun 7.

PMID:
18588904

Supplemental Content

Loading ...
Support Center